Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15INK4b methylation status

Abstract

The cell cycle inhibitor p15INK4B is frequently inactivated by homozygous deletions together with p16INK4a/p14ARF in many tumour types. Although it is now well established that p16INK4a and p14ARF act as tumour suppressor genes, the role of p15INK4b remains to be well defined. In order to explore the possibility of a selective deregulation of p15INK4b in human lung carcinogenesis, we studied p15INK4b status in neuroendocrine (NE) lung tumours where homozygous deletions of the p16INK4a/p14ARF locus are rarely observed. Expressions of p15 and p15.5 protein isoforms were analysed in a series of eight control normal lung, 12 tumour-associated normal lung, five low grade and 15 high grade neuroendocrine (NE) lung tumours and relationship with a specific p15INK4b methylation status was studied. Using Western blot analysis, we showed that p15 and p15.5 isoforms displayed a high heterogeneous pattern of expression in both normal and tumour tissues. P15 and p15.5 expressions were correlated in control normal lung (P<0.04) whereas they were not in tumours and associated normal lung. The level of p15.5 was significantly higher in associated normal lung and in tumours (P<0.02 respectively), specially in low grade tumours (P<0.01), than in control normal lung. Furthermore, p15.5 expression was more variable in tumours than in normal lung (P<0.01) and in low grade than in high grade NE lung tumours (P<0.02). Levels of p15 and p15.5 were distinct (up- or downregulated) from those observed in paired normal lung in 4/12 (33%) and 10/12 (83%) tumours respectively. Aberrant methylation at the 5′ end of p15INK4b gene was observed in 15% of NE lung tumours using PCR-based assay, in a region proximal to the translation start where methylation did not occur in control and associated normal lung. However, no correlation could be assessed with protein status. MSP analysis of CpG islands proximal to the transcription start revealed methylation in all normal and tumour samples. No correlation was found between p15INK4b and p16INK4a or p14ARF status. These data suggest that complex deregulation of p15.5 is implicated in the carcinogenesis of human NE lung tumours independently of p16INK4a and p14ARF status.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Aggerholm A, Guldberg P, Hokland M, Hokland P . 1999 Cancer Res. 59: 436–441

  • Anbazhagan R, Tihan T, Bornman DM, Johnston JC, Saltz JH, Weigering A, Piantadosi S, Gabrielson E . 1999 Cancer Res. 59: 5119–5122

  • Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D . 1995 Nature Genet. 11: 210–212

  • Cameron E, Baylin SB, Herman JG . 1999 Blood 94: 2445–2451

  • Chin L, Pomerantz J, DePinho RA . 1998 Trends Biochem. Sci. 23: 291–296

  • Della Valle V, Duro D, Bernard O, Larsen CJ . 1997 Oncogene 15: 2475–2481

  • Dosaka-Akita H, Cagle PT, Hiroumi H, Fujita M, Yamashita M, Sharma A, Kawakami Y, Benedict WF . 2000 Cancer 88: 550–556

  • Fuxe J, Raschperger E, Pettersson RF . 2000 Oncogene 19: 1724–1728

  • Gazzeri S, Gouyer V, Vour'ch C, Brambilla C, Brambilla E . 1998a Oncogene 16: 497–504

  • Gazzeri S, Della Valle V, Chaussade L, Brambilla C, Larsen CJ, Brambilla E . 1998b Cancer Res. 58: 3926–3931

  • Glendening JM, Flores JF, Walker GJ, Stone S, Albino AP, Fountain JW . 1995 Cancer Res. 55: 5531–5535

  • Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA . 1995 Cancer Res. 55: 4531–4535

  • Gray-Gablin J, Rao S, Keyomarsi K . 1997 Cancer Res. 57: 604–609

  • Hamada K, Kohno T, Kawanishi M, Ohwada S, Yokota J . 1998 Genes. Chrom. Cancer 22: 232–240

  • Hannon GJ, Beach D . 1994 Nature (Lond.) 371: 257–261

  • Harper JW, Elledge SJ . 1996 Curr. Opin. Genet. Dev. 6: 56–64

  • Herman JG, Jen J, Merlo A, Baylin SB . 1996a Cancer Res. 56: 722–727

  • Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB . 1996b Proc. Natl. Acad. Sci. USA 93: 9821–9826

  • Herman JG, Civin CI, Issa JPJ, Collector MI, Sharkis SJ, Baylin SB . 1997 Cancer Res. 57: 837–841

  • Hunter T, Pines J . 1994 Cell 79: 573–582

  • Iravani M, Daht R, Price C . 1997 Oncogene 15: 2609–2614

  • Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B . 1994 Cancer Res. 54: 6353–6358

  • Kamb A, Gruis NA, Weaver-feldhaus J, liu Q, Harsham K, Tavtigian SV, Stockert E, Day RS, Johnson BE, Skolnick MH . 1994 Science 264: 436–440

  • Latres E, Malumbres M, Sotillo R, Martin J, Ortega S, Martin-Caballero J, Flores JM, Cordon-Cardo C, Barnacid M . 2000 EMBO J. 13: 3496–3506

  • Li JM, Nichols MA, Chandrasekharan S, Xiong Y, Wang XF . 1995 J. Biol. Chem. 270: 26750–26753

  • Medema RH, Herrera RE, Lam F, Weinberg RA . 1995 Proc. Natl. Acad. Sci. USA 92: 6289–6293

  • Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D . 1995 Nature. Med. 1: 686–692

  • Nakagawa K, Conrad N, Williams J . 1995 Oncogene 11: 1843–1851

  • Okamoto A, Hussain SP, Hagiwara K, Spillare EA, Rusin MR, Demetrick DJ, Serrano M, Hannon GJ, Shiseki M, Zariwala M, Xiong Y, Beach DH, Yokota J, Harris CC . 1995 Cancer Res. 55: 1448–1451

  • Packenham JP, Taylor JA, White CM, Anna CH, Barrett JC, Devereux TR . 1995 Clin Cancer Res. 1: 687–690

  • Pollock PM, Pearson JV, Hayward NK . 1996 Genes Chrom. Cancer. 15: 77–88

  • Rasool O, Heyman M, Brandter LB, Liu Y, Grander D, Soderhall S, Einhorn S . 1995 Blood 85: 3431–3436

  • Reynisdottir I, Polyak K, Iavarone A, Massgue J . 1995 Genes Dev. 9: 1831–1845

  • Rusin MR, Okamoto A, Chorazy M, Czyzewski K, Harasim J, Spillare EA, Hagiwara K, Perwez Hussain S, Xiong Y, Demetrick DJ, Harris CC . 1996 Int. J. Cancer. 65: 734–739

  • Sangfelt O, Erickso S, Einhorn S, Grander D . 1997 Oncogene. 14: 415–423

  • Sharpless NE, DePinho RA . 1999 Curr. Opin. Genet. Dev. 9: 22–30

  • Sherr CJ . 1996 Science. 274: 1672–1677

  • Sherr CJ, Robert JM . 1995 Genes Dev. 13: 1501–1512

  • Sherr CJ . 1998 Genes Dev. 12: 2984–2991

  • Stone S, Dayananth P, Jiang P, Weaver-Geldhous JM, Tavtigian SV, Cannon-Albright L, Kamb A . 1995 Oncogene 11: 987–991

  • Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E . 1999 EMBO J. 18: 4280–4291

  • Tsubari M, Tiihonen E, Laiho M . 1997 Cancer Res. 57: 2966–2973

  • Washimi O, Nagatake M, Osada H . 1995 Cancer Res. 55: 514–517

  • Xiao S, Li D, Corson JM, Vijg J, Fletcher JA . 1995 Cancer Res. 55: 2968–2971

  • Yuan J, Knorr J, Altmannsberger M, Goeckenjan G, Ahr A, Scharl A, Strebhardt K . 1999 J. Pathol. 189: 358–362

Download references

Acknowledgements

We thank C Oddou and P Perron for technical assistance. This work was supported by grants from the Association pour la Recherche sur le Cancer, from the Comité Départemental de la Ligue contre le Cancer de l'Isère et de la Vienne and from the Groupement des Entreprises Françaises dans la lutte contre le Cancer. L Chaussade held a fellowship from the Ministère de la Recherche et de la Technologie and B Eymin was supported by INSERM (Poste d'accueil).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sylvie Gazzeri.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chaussade, L., Eymin, B., Brambilla, E. et al. Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15INK4b methylation status. Oncogene 20, 6587–6596 (2001). https://doi.org/10.1038/sj.onc.1204798

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204798

Keywords

This article is cited by

Search

Quick links